玻璃体内注射地塞米松治疗中心静脉阻塞所致黄斑水肿患者48周随访后的形态学和功能转归
Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up.
作者信息
Nicula Cristina, Nicula Dorin, Rednik Anca, Bulboaca Adriana, Crișan Ovidiu
机构信息
University of Medicine and Pharmacy "Iuliu Hațieganu", Faculty of Medicine, Department of Ophthalmology, Cluj-Napoca, Romania.
Oculens Clinic, Cluj-Napoca, Romania.
出版信息
J Ophthalmol. 2020 Feb 11;2020:6830148. doi: 10.1155/2020/6830148. eCollection 2020.
PURPOSE
The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. . A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to retinal vein occlusion (RVO) who undertook intravitreal Ozurdex® as first-line treatment. We performed a complete ocular exam including macular OCT.
RESULTS
The mean BCVA (logMar) improved from 0.420.42 ± 0.23 logMar at baseline to 0.21 ± 0.23 logMar at 48 weeks in the BRVO group and from 0.72 ± 0.16 logMar at baseline to 0.31 ± 0.23 logMar at 48 weeks in the CRVO group. In both groups, CFT values decreased significantly compared to baseline ( < 0.0001 at each timepoint). Reinjection for recurrent macular edema after 18 weeks was indicated in five eyes (41.67%) in the BRVO group and in six eyes (25%) in the CRVO group. Cataract developed in two eyes (16.67%) in the BRVO group and in one eye (4.17%) in the CRVO group. The IOP was higher than 25 mmHg in two cases in the BRVO group (16.66%) and in three cases (8.33%) in the CRVO group.
CONCLUSION
Ozurdex® injected intravitreally significantly improved the mean CFT and BCVA in eyes with macular edema due to retinal vein occlusion.
目的
本研究旨在评估玻璃体内注射地塞米松植入剂（IDI：Ozurdex®）治疗视网膜静脉阻塞所致黄斑水肿的疗效。对因视网膜静脉阻塞（RVO）导致黄斑水肿（ME）且接受玻璃体内Ozurdex®作为一线治疗的患者进行了一项回顾性、非随机研究。我们进行了包括黄斑OCT在内的完整眼部检查。
结果
BRVO组的平均最佳矫正视力（logMar）从基线时的0.42±0.23 logMar提高到48周时的0.21±0.23 logMar，CRVO组从基线时的0.72±0.16 logMar提高到48周时的0.31±0.23 logMar。在两组中，与基线相比，中央黄斑厚度（CFT）值均显著降低（每个时间点P<0.0001）。BRVO组有5只眼（41.67%）、CRVO组有6只眼（25%）在18周后因复发性黄斑水肿而需要再次注射。BRVO组有2只眼（16.67%）、CRVO组有1只眼（4.17%）发生了白内障。BRVO组有2例（16.66%）、CRVO组有3例（8.33%）眼压高于25 mmHg。
结论
玻璃体内注射Ozurdex®可显著改善视网膜静脉阻塞所致黄斑水肿患者的平均CFT和最佳矫正视力。
Zotero 插件